Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates

被引:93
作者
Boyle-Vavra, S
Berke, SK
Lee, JC
Daum, RS
机构
[1] Univ Chicago, Childrens Hosp, Dept Pediat, Chicago, IL 60637 USA
[2] Harvard Univ, Brigham & Womens Hosp, Channing Lab, Dept Med,Sch Med, Boston, MA 02115 USA
关键词
D O I
10.1128/AAC.44.2.272-277.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The recent identification of glycopeptide intermediate-resistant Staphylococcus aureus (GISA) clinical isolates has provided an opportunity to assess the stability of the glycopeptide resistance phenotype by nonselective serial passage and to evaluate reversion-associated cell surface changes. Three GISA isolates from the United States (MIC of vancomycin = g mu g/ml) and two from Japan (MICs of vancomycin = 8 and 2 mu g/ml) were passaged daily on nutrient agar with or without vancomycin supplementation, After 15 days of passage on nonselective medium, vancomycin- and teicoplanin-susceptible revertants were obtained from each GISA isolate as determined by broth dilution MIG. Revertant isolates were compared,vith parent isolates for changes in vancomycin heteroresistance, capsule production, hemolysis phenotype, coagulase activity, and lysostaphin susceptibility. Several revertants lost the subpopulations with intermediate vancomycin resistance, whereas two revertants maintained them. Furthermore, although all of the parent GISA isolates produced capsule type 5 (CP5), all but one revertant tested no longer produced CP5. In contrast, passage on medium containing vancomycin yielded isolates that were still intermediately resistant to vancomycin, had no decrease in the MIC of teicoplanin, and produced detectable CP5, No consistent changes in the revertants in hemolysis phenotype, lysostaphin susceptibility, or coagulase activities were discerned. These data indicate that the vancomycin resistance phenotype is unstable in clinical GISA isolates. Reversion of the vancomycin resistance phenotype might explain the difficulty in isolating vancomycin-resistant clinical isolates from the blood of patients who fail vancomycin therapy and, possibly, may account for some of the difficulties in identifying GISA isolates in the clinical laboratory.
引用
收藏
页码:272 / 277
页数:6
相关论文
共 30 条
  • [11] SLOW RESPONSE TO VANCOMYCIN OR VANCOMYCIN PLUS RIFAMPIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS
    LEVINE, DP
    FROMM, BS
    REDDY, BR
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (09) : 674 - 680
  • [12] DECREASED TEICOPLANIN SUSCEPTIBILITY OF METHICILLIN-RESISTANT STRAINS OF STAPHYLOCOCCUS-AUREUS
    MAINARDI, JL
    SHLAES, DM
    GOERING, RV
    SHLAES, JH
    ACAR, JF
    GOLDSTEIN, FW
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (06) : 1646 - 1650
  • [13] Antimicrobial resistance in staphylococci - Epidemiology, molecular mechanisms, and clinical relevance
    Maranan, MC
    Moreira, B
    BoyleVavra, S
    Daum, RS
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1997, 11 (04) : 813 - +
  • [14] Maslow Joel N., 1993, P563
  • [15] Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus
    Moreira, B
    BoyleVavra, S
    deJonge, BLM
    Daum, RS
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) : 1788 - 1793
  • [16] *NAT COMM CLIN LAB, 1999, M100S9 NAT COMM CLIN, V19
  • [17] National Committee for Clinical Laboratory Standards, 1997, METH DIL ANT SUSC TE, V17
  • [18] Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia
    Rotun, SS
    McMath, V
    Schoonmaker, DJ
    Maupin, PS
    Tenover, FC
    Hill, BC
    Ackman, DM
    [J]. EMERGING INFECTIOUS DISEASES, 1999, 5 (01) : 147 - 149
  • [19] Shimada K, 1995, JPN J CHEMOTHER, V43, P1048
  • [20] TEICOPLANIN-RESISTANT STAPHYLOCOCCUS-AUREUS EXPRESSES A NOVEL MEMBRANE-PROTEIN AND INCREASES EXPRESSION OF PENICILLIN-BINDING PROTEIN-2 COMPLEX
    SHLAES, DM
    SHLAES, JH
    VINCENT, S
    ETTER, L
    FEY, PD
    GOERING, RV
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) : 2432 - 2437